Citation & Authors
Diabetes Obes Metab. 2025;27(11):6403-6415.
ABSTRACT · RESEARCH SUMMARY
Research summary
The TriNetX study used basal insulin, DPP-4 inhibitors, and SGLT2 inhibitors as active comparators. GLP-1 receptor agonists were associated with lower risks of incident IBD than the first two comparators (HRs 0.725 and 0.814), and with lower hospitalization risks in all three comparisons. The abstract did not report a significant reduction in IBD risk versus SGLT2 inhibitors; the findings should not be treated as identical across all comparisons.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
